{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:37:40Z","timestamp":1775151460637,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.jcv.2007.02.003","type":"journal-article","created":{"date-parts":[[2007,3,22]],"date-time":"2007-03-22T11:00:49Z","timestamp":1174561249000},"page":"43-47","source":"Crossref","is-referenced-by-count":33,"title":["No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: Impact of resistant minority variants on efficacy of low genetic barrier drugs"],"prefix":"10.1016","volume":"39","author":[{"given":"Kristel","family":"Van Laethem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"De Munter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoeri","family":"Schrooten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Verbesselt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Van Ranst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Van Wijngaerden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Mieke","family":"Vandamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2007.02.003_bib1","doi-asserted-by":"crossref","first-page":"8390","DOI":"10.1128\/JVI.74.18.8390-8401.2000","article-title":"Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNaseH cleavage that correlate with HIV-1 replication fitness in cell culture","volume":"74","author":"Archer","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.jcv.2007.02.003_bib2","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1097\/00002030-200411190-00007","article-title":"A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV","volume":"18","author":"Benson","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2007.02.003_bib3","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1128\/JCM.41.6.2792-2794.2003","article-title":"Algorithm specification interface for human immunodeficiency virus type 1 genotypic interpretation","volume":"41","author":"Betts","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcv.2007.02.003_bib4","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200301030-00001","article-title":"A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors","volume":"17","author":"Brenner","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2007.02.003_bib5","first-page":"S132","article-title":"Mapping nevirapine and efavirenz resistance using Bayesian networks of HIV-1 pol sequences of subtypes A, B, C, F and G","volume":"10","author":"Deforche","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jcv.2007.02.003_bib6","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1097\/00126334-200412150-00022","article-title":"Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response","volume":"37","author":"Derdelinckx","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jcv.2007.02.003_bib7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2007.02.003_bib8","doi-asserted-by":"crossref","first-page":"13907","DOI":"10.1073\/pnas.241300698","article-title":"Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons","volume":"98","author":"Garcia-Lerma","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.jcv.2007.02.003_bib9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.296.7.827","article-title":"Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel","volume":"296","author":"Hammer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jcv.2007.02.003_bib10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/381784","article-title":"Genotypic and phenotypic predictors of the magnitude of response to tenofovir disproxil fumarate treatment in antiretroviral-experienced patients","volume":"189","author":"Miller","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2007.02.003_bib11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/135965350400900514","article-title":"Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe","volume":"9","author":"Pillay","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jcv.2007.02.003_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/088922202753472801","article-title":"Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program","volume":"18","author":"Schuurman","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jcv.2007.02.003_bib13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/135965350400900619","article-title":"Updated European recommendations for the clinical use of HIV drug resistance testing","volume":"9","author":"Vandamme","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jcv.2007.02.003_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00042560-199910010-00001","article-title":"Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations","volume":"22","author":"Van Laethem","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jcv.2007.02.003_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/135965350200700206","article-title":"A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1 infected patients","volume":"7","author":"Van Laethem","year":"2002","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jcv.2007.02.003_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/135965350100600107","article-title":"Prevalence of genotypic resistance among antiretroviral drug-na\u00efve HIV-1-infected patients in Belgium","volume":"6","author":"Van Vaerenbergh","year":"2001","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jcv.2007.02.003_bib17","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1086\/432916","article-title":"Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management","volume":"192","author":"Wensing","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2007.02.003_bib18","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/378281","article-title":"Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates","volume":"188","author":"Whitcomb","year":"2003","journal-title":"J Infect Dis"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653207000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653207000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T04:02:32Z","timestamp":1683777752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653207000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S1386653207000686"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2007.02.003","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}